Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- Alzheimer Disease & Dementias
Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease
Luka Kulic, MDLuka Kulic, MD - Alzheimer Disease & Dementias
Establishing a Sustainable Amyloid-Targeting Treatment Program: Lessons from One Institution
Rachel Hart, DORachel Hart, DO - Alzheimer Disease & Dementias
Alzheimer Disease: Real-World Approaches to Patient Care
Gregory E. Cooper, MD, PhD, FAANGregory E. Cooper, MD, PhD, FAAN - Alzheimer Disease & Dementias
Early Alzheimer Disease Detection through a Davos Initiative: Building Communities of Practice for Sustainable Change
Elyse Perweiler, RN, MPP; Tim MacLeod, PhDElyse Perweiler, RN, MPP; Tim MacLeod, PhD
